The FDA's AI Diagnostic Approval Is Closer Than Most Think
Google's Med-Gemini just achieved 96% accuracy in chest X-ray reports, surpassing radiologists in typical cases — the latest in a cascade of AI systems demonstrating superior diagnostic performance. TexTak places FDA approval of the first fully autonomous AI diagnostic at 55%, and today's evidence suggests that probability may be conservative. The technical barriers have largely fallen; what remains are institutional and liability frameworks that mounting cost pressure may finally force into adaptation.
Our 55% reflects two competing realities: AI diagnostic superiority is now routine, but regulatory frameworks still assume human oversight. Med-Gemini's performance represents more than incremental improvement — it's crossing the threshold where AI reliability exceeds human baseline in controlled settings. With 500+ AI medical devices already FDA-cleared and the agency signaling openness to adaptive frameworks, the infrastructure exists. The economic pressure is undeniable: healthcare systems bleeding money on radiologist shortages while AI sits ready to fill the gap.
The counterargument remains formidable: liability frameworks don't exist yet, and the AMA continues lobbying against physician oversight removal. Every current FDA approval still requires human review for final decisions, creating a regulatory moat that protects established practice patterns. The transition from "AI-assisted" to "AI-autonomous" requires crossing a liability chasm that no regulator wants to be first to bridge.
Honestly, what keeps us from moving higher is the gap between technical readiness and institutional courage. Radiologists aren't just being outperformed — they're being outperformed consistently across multiple studies, yet the regulatory response remains cautious. The economic pressure may be the forcing function we're underweighting. When health systems face bankruptcy-level staffing costs while proven AI solutions sit on the shelf, something has to give.
What moves us above 65%? A major health system publicly committing to physician-free AI diagnostics contingent on regulatory approval, or CMS announcing reimbursement frameworks for autonomous AI decisions. What drops us below 45%? Congressional hearings on AI medical liability or high-profile misdiagnosis cases attributed to AI systems. We're watching Q3 healthcare earnings calls for signals that cost pressure is reaching breaking points.